← Leaderboards
Daniel Starczynowski
Cincinnati Childrens Hosp Med Ctr
$17,551,895
Attributed
$20,587,223
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,847,858 · 12
By mechanism
R01$11,781,514 · 7
R35$7,892,274 · 2
U54$5,174,070 · 3
Top collaborators
- Yi Zheng5 shared
- Iannis Aifantis4 shared
- Amit Verma4 shared
- Mohammad Azam3 shared
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- Mohammad Azam$5,839,846
- Jose A. Cancelas$9,659,208
- Samuel Goldfarb$2,417,127
Others in their field
Top investigators on “Genetic”
- Richard A Gibbs · Baylor College Of Medicine$577,061,667
- Eric S Lander · Whitehead Institute For Biomedical Res$560,806,052
- David R. Weir · University Of Michigan At Ann Arbor$322,225,557
- Richard K. Wilson · Washington University$316,685,275
- Lawrence Corey · Fred Hutchinson Cancer Center$312,182,347
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$302,429,647
Research focus
GeneticMolecularCellsMouse ModelDysmyelopoietic SyndromesHematopoietic Stem CellsHematopoieticIn VivoCell PhysiologySignal TransductionCollectionBlood CellsPathway InteractionsBaseGenesChronicMediatingImmuneBone MarrowPublicationsMutationNovel TherapeuticsLeukemiaHematopoiesis
Grant awards (45)
Decoding innate immune signaling in normal and myelodysplastic hematopoiesis$1,090,808
R35 · FY2025 · HL · contact PI
Cincinnati Cooperative Center of Excellence in Hematology$852,127
U54 · FY2025 · DK
Dissecting innate immune signaling in pre-leukemia evolution$638,243
R01 · FY2025 · CA · contact PI
Therapeutic targeting of IRAK4 in MDS$528,024
R01 · FY2025 · CA
Xenotransplant and Genome Editing Core$182,683
U54 · FY2025 · DK · contact PI
Decoding innate immune signaling in normal and myelodysplastic hematopoiesis$1,080,025
R35 · FY2024 · HL · contact PI
Cincinnati Cooperative Center of Excellence in Hematology$852,127
U54 · FY2024 · DK
Dissecting innate immune signaling in pre-leukemia evolution$606,333
R01 · FY2024 · CA · contact PI
Therapeutic targeting of IRAK4 in MDS$501,623
R01 · FY2024 · CA
Xenotransplant and Genome Editing Core$182,683
U54 · FY2024 · DK · contact PI
Decoding innate immune signaling in normal and myelodysplastic hematopoiesis$1,113,000
R35 · FY2023 · HL · contact PI
Cincinnati Cooperative Center of Excellence in Hematology$852,127
U54 · FY2023 · DK
Dissecting innate immune signaling in pre-leukemia evolution$625,479
R01 · FY2023 · CA · contact PI
Therapeutic targeting of IRAK4 in MDS$517,464
R01 · FY2023 · CA
Xenotransplant and Genome Editing Core$182,683
U54 · FY2023 · DK · contact PI
Cincinnati Cooperative Center of Excellence in Hematology$852,127
U54 · FY2022 · DK
Decoding innate immune signaling in normal and myelodysplastic hematopoiesis$715,959
R35 · FY2022 · HL · contact PI
Dissecting innate immune signaling in pre-leukemia evolution$652,991
R01 · FY2022 · CA · contact PI
Therapeutic targeting of IRAK4 in MDS$545,024
R01 · FY2022 · CA
Mechanism of Therapy in high-risk AML$478,645
R01 · FY2022 · CA
Xenotransplant and Genome Editing Core$182,703
U54 · FY2022 · DK · contact PI
Cincinnati Cooperative Center of Excellence in Hematology$852,127
U54 · FY2021 · DK
Decoding innate immune signaling in normal and myelodysplastic hematopoiesis$737,482
R35 · FY2021 · HL · contact PI
Mechanism of Therapy in high-risk AML$488,415
R01 · FY2021 · CA
Xenotransplant and Genome Editing Core$182,683
U54 · FY2021 · DK · contact PI
Decoding innate immune signaling in normal and myelodysplastic hematopoiesis$788,750
R35 · FY2020 · HL · contact PI
Mechanism of Therapy in high-risk AML$488,415
R01 · FY2020 · CA
Targeting IRAK1/4 in Myelodysplastic Syndromes$481,139
R01 · FY2020 · DK · contact PI
Decoding innate immune signaling in normal and myelodysplastic hematopoiesis$788,750
R35 · FY2019 · HL · contact PI
Targeting IRAK1/4 in Myelodysplastic Syndromes$481,139
R01 · FY2019 · DK · contact PI
Decoding innate immune signaling in normal and myelodysplastic hematopoiesis$788,750
R35 · FY2018 · HL · contact PI
Targeting IRAK1/4 in Myelodysplastic Syndromes$485,824
R01 · FY2018 · DK · contact PI
Decoding innate immune signaling in normal and myelodysplastic hematopoiesis$788,750
R35 · FY2017 · HL · contact PI
Targeting IRAK1/4 in Myelodysplastic Syndromes$491,203
R01 · FY2017 · DK · contact PI
Role of TRAF6 in Myelodysplastic Syndromes$398,308
R01 · FY2016 · HL · contact PI
Identification and characterization of genes in del(5q) myelodysplastic syndrome$382,500
R01 · FY2016 · HL · contact PI
Molecular Pathogenesis of MDS$233,135
R01 · FY2016 · DK · contact PI
Role of TRAF6 in Myelodysplastic Syndromes$392,716
R01 · FY2015 · HL · contact PI
Identification and characterization of genes in del(5q) myelodysplastic syndrome$376,762
R01 · FY2015 · HL · contact PI
Molecular Pathogenesis of MDS$234,000
R01 · FY2015 · DK · contact PI
Role of TRAF6 in Myelodysplastic Syndromes$398,642
R01 · FY2014 · HL · contact PI
Identification and characterization of genes in del(5q) myelodysplastic syndrome$374,850
R01 · FY2014 · HL · contact PI
Molecular Pathogenesis of MDS$234,000
R01 · FY2014 · DK · contact PI
Identification and characterization of genes in del(5q) myelodysplastic syndrome$364,140
R01 · FY2013 · HL · contact PI
Identification and characterization of genes in del(5q) myelodysplastic syndrome$382,500
R01 · FY2012 · HL · contact PI